Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

PSMA inhibitor

DRUG CLASS:

PSMA inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

FOLH1 positive	Prostate Cancer	FOLH1 positive	Prostate Cancer	lutetium Lu 177 vipivotide tetraxetan Sensitive: A1 - Approval lutetium Lu 177 vipivotide tetraxetan Sensitive : A1	lutetium Lu 177 vipivotide tetraxetan Sensitive: A1 - Approval lutetium Lu 177 vipivotide tetraxetan Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	lutetium Lu 177 vipivotide tetraxetan Sensitive: B - Late Trials lutetium Lu 177 vipivotide tetraxetan Sensitive : B	lutetium Lu 177 vipivotide tetraxetan Sensitive: B - Late Trials lutetium Lu 177 vipivotide tetraxetan Sensitive : B
FOLH1 expression	Prostate Cancer	FOLH1 expression	Prostate Cancer	PNT2002 Sensitive: B - Late Trials PNT2002 Sensitive : B	PNT2002 Sensitive: B - Late Trials PNT2002 Sensitive : B
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	PNT2002 Sensitive: B - Late Trials PNT2002 Sensitive : B	PNT2002 Sensitive: B - Late Trials PNT2002 Sensitive : B
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	225Ac-FL-020 Sensitive: B - Late Trials 225Ac-FL-020 Sensitive : B	225Ac-FL-020 Sensitive: B - Late Trials 225Ac-FL-020 Sensitive : B
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	cemiplimab-rwlc + INO-5401 + INO-9012 Sensitive: C3 – Early Trials cemiplimab-rwlc + INO-5401 + INO-9012 Sensitive : C3	cemiplimab-rwlc + INO-5401 + INO-9012 Sensitive: C3 – Early Trials cemiplimab-rwlc + INO-5401 + INO-9012 Sensitive : C3
FOLH1 expression	Prostate Cancer	FOLH1 expression	Prostate Cancer	pembrolizumab + lutetium Lu 177 vipivotide tetraxetan Sensitive: C3 – Early Trials pembrolizumab + lutetium Lu 177 vipivotide tetraxetan Sensitive : C3	pembrolizumab + lutetium Lu 177 vipivotide tetraxetan Sensitive: C3 – Early Trials pembrolizumab + lutetium Lu 177 vipivotide tetraxetan Sensitive : C3
ATM mutation	Prostate Cancer	ATM mutation	Prostate Cancer	enzalutamide + lutetium Lu 177 vipivotide tetraxetan Sensitive: C4 – Case Studies enzalutamide + lutetium Lu 177 vipivotide tetraxetan Sensitive : C4	enzalutamide + lutetium Lu 177 vipivotide tetraxetan Sensitive: C4 – Case Studies enzalutamide + lutetium Lu 177 vipivotide tetraxetan Sensitive : C4
FOLH1 expression	Prostate Cancer	FOLH1 expression	Prostate Cancer	JNJ-63898081 Sensitive: D – Preclinical JNJ-63898081 Sensitive : D	JNJ-63898081 Sensitive: D – Preclinical JNJ-63898081 Sensitive : D